New MedPredict Report Provides Thought Leader Ranking of Inflammatory Bowel Disease Compounds in Development

Share Article

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report in its gastroenterology series entitled “Thought Leader Insight & Analysis: Crohn’s Disease, Ulcerative Colitis,” designed to provide critical strategic insight for pharma and biotech companies with a stake in these markets. MedPredict interviewed renowned North American gastroenterology thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report in its gastroenterology series entitled “Thought Leader Insight & Analysis: Crohn’s Disease, Ulcerative Colitis,” designed to provide critical strategic insight for pharma and biotech companies with a stake in these markets. MedPredict interviewed renowned North American gastroenterology thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs.

“In our last Gastroenterology Thought Leader Panel we reported on key unmet needs in the treatment of Crohn’s disease and ulcerative colitis,” says Dr. Jeff Berk, president of MedPredict. “In this report we ask six internationally recognized experts in the treatment of inflammatory bowel disease (IBD) to build on that, and engage with us in a thought exercise with the aim of ranking the most medically valuable initiatives in the developmental pipeline.”

The report also addresses the more immediately commercially relevant question of comparing Simponi to other anti-TNF agents, next generation inhibitors of leukocyte trafficking to natalizumab and to each other, and both of these classes to p40 approaches.

The Panel was well represented by both very aggressive treaters – those looking for stem cell transplants for everybody, and the very conservative treater who is looking to replace (whenever possible) biologicals and immunomodulators with more natural, homeopathic medicines. Each side makes their case.

Finally, Panelists comment on recent clinical setbacks for Humira in ulcerative colitis, and thoughts on Cimzia, 5-ASA products, new steroids, probiotics, oral small molecules (tasocitinib, apremilast, others) and newer biological approaches (e.g. IL-17, innate immunostimulators).

Companies discussed in this report include: Abbott (Eisai), ActoGeniX, Alizyme, Allostera, Ardeypharm, Avaxia, Bayer-Schering, Celgene, ChemoCentryx/GlaxoSmithKline, Cosmos/Santarus, Elan/Biogen, Genentech/Roche, J&J/Centocor/Merck/Essex, Merck (Schering-Plough), Milllennium/Takeda, Novartis, Osiris Therapeutics, Pfizer, Salix, Shire, Teva, UCB, and Warner Chilcott.

The full report can be purchased by contacting MedPredict.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924
liz(at)medpredict(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
MedPredict
(513) 271-1924
Email >
Visit website